Search

Displaying results 711 - 720 of 2507 in total
  1. Drug

    Ornithine

    go.drugbank.com/drugs/DB00129
    ApprovedInvestigationalNutraceutical

    Produced during the urea cycle, ornithine is an amino acid produced from the splitting off of urea from arginine. L-Ornithine allows for the disposal of excess nitrogen and acts as a precursor of citrulline and arginine.

    Mixtures: GNC PP L-Arginine L-Ornithine Tablet
  2. Drug

    Dihydrocodeine

    go.drugbank.com/drugs/DB01551
    ApprovedIllicit

    Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to ...

    Mixtures: Coldcough PDCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Substrates
  3. Drug

    Caffeine

    go.drugbank.com/drugs/DB00201
    ApprovedInvestigational

    Caffeine is a drug of the methylxanthine class used for a variety of purposes, including certain respiratory conditions of the premature newborn, pain relief, and to combat drowsiness. Caffeine is similar in chemical structure to Theophy...

    Mixtures: NEXT-TABS, Cafergot Pb TabCategories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP1A2 Inhibitors
  4. Drug

    SF1126

    go.drugbank.com/drugs/DB05210
    Investigational

    SF1126 is an integrin-targeted PI3 kinase inhibitor.

  5. Drug

    SGN-15

    go.drugbank.com/drugs/DB05818
    Investigational

    SGN-15 is studied in the treatment of cancer. It combines a monoclonal antibody with the anticancer drug doxorubicin. Monoclonal antibodies are substances that are made in the laboratory and that can locate and bind to cancer cells. Doxo...

  6. Drug

    Anpocogin

    go.drugbank.com/drugs/DB06552
    Investigational

    Recombinant nematode anticoagulant protein c2 (rNAPc2) is a specific inhibitor of tissue factor (TF)/factor VIIa complex with novel antithrombotic activity.

  7. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substr...

  8. Drug

    Diclofenac

    go.drugbank.com/drugs/DB00586
    ApprovedInvestigationalVet approved

    Diclofenac is a phenylacetic acid derivative and non-steroidal anti-inflammatory drug (NSAID).[label] NSAIDs inhibit cyclooxygenase (COX)-1 and-2 which are the enzyme responsible for producing prostaglandins (PGs). PGs contribute to infl...

    Categories: P-glycoprotein inducers, Cytochrome P-450 Substrates
  9. Drug

    Hydrochlorothiazide

    go.drugbank.com/drugs/DB00999
    ApprovedInvestigationalVet approved

    Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension. Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combinati...

    Mixtures: ENALAPRIL 1A PL 20/6MG, ENALAPRIL 1A PL 20/6MG
  10. Drug

    Irbesartan

    go.drugbank.com/drugs/DB01029
    ApprovedInvestigational

    Irbesartan is an angiotensin receptor blocker (ARB) indicated to treat hypertension or diabetic nephropathy. It can also be used as part of a combination product with hydrochlorothiazide for patients not well controlled or not expected t...

    Mixtures: IRBESARTAN COM PU 300/25, IRBESARTAN COM PU 300/25Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A Inhibitors